IL-6 and IL-6 Receptor Proteins
In 1973, Interleukin 6 (IL-6) was identified as a soluble factor secreted by T cells, which is essential for the production of antibodies by B cells. Since its discovery nearly 50 years ago, the IL-6 signaling pathway has emerged as a key pathway involved in immune regulation in health and immune dysregulation in many diseases.
In the classical pathway, IL-6 binds to the membrane-bound IL-6 receptor (IL-6R), and this complex subsequently associates with gp130, triggering downstream signaling. In the trans-signaling pathway, IL-6 binds to the soluble form of its receptor (IL-6R), and this IL-6/IL-6R complex then binds to gp130 to initiate intracellular signaling. In the next step, the JAK-STAT, RAS-RAF, and other pathways are activated, promoting cellular proliferation, differentiation, oxidative stress, and immune regulation. The classical IL-6 signal is limited to the cells (macrophages, neutrophils, T cells, etc.) that express IL-6R. But when IL-6 levels are elevated, the signal is widely expressed due to the ubiquitous nature of gp130.
IL-6 signaling pathway
Furthermore, emerging evidence suggests that dysregulation of IL-6 contributes to a variety of disease states, including various types of cancer development, progression, and metastasis, increased levels of IL-6 are associated with a higher risk of cancer and other diseases, such as insulin resistance, asthma, coronary heart disease, advanced cancer, and can also serve as a prognostic marker for cancer. Targeting this pathway may expand to the treatment of several other symptoms, such as uveitis, neuromyelitis optica, and more recently, COVID-19 pneumonia.
ACROBiosystems has developed a series of high-quality IL-6 and IL-6 receptor proteins to facilitate the development of IL-6 related drugs.
Product Features
Human and Mouse species are available
High purity: >95%
High bioactivity verified by ELISA, BLI and cell-based assay. Free protocols offered
Various tags：Tag Free，His Tag，Avi & His Tag，Fc Tag
Low endotoxin：＜ 1.0 EU/μg
OrderVerification Data
High purity is more than 95% as verified by SDS-PAGE
Biotinylated Human IL-6 R alpha, Avitag, His Tag (Cat. No. CD6-H82E8) on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%. The protein has a calculated MW of 41.7 kDa and migrates as 55-70 kDa due to glycosylation.
High bioactivity verified by cell-based assay
ActiveMax® Human IL-6, Tag Free (Cat. No. IL6-H4218) stimulates proliferation of TF-1 human erythroleukemic cell line. The EC50 for this effect is 0.2856-0.3636 ng/mL.
Biotinylated Human IL-6, epitope tag free, primary amine labeling (Cat. No. IL6-H8218) stimulates proliferation of TF-1 human erythroleukemic cell line. The EC50 for this effect is 0.2532-0.4489 ng/mL.
Related Reading
＞＞【Inspiring Target】Therapeutic potential of IL-6 immunization in multiple fields continues to burst
References
1. Translating IL-6 biology into effective treatments. Nat Rev Rheumatol 16, 335–345 (2020).
-
Authors:Choy, E.H., De Benedetti, F., Takeuchi, T. et al.
2. IL-6 Inhibitors in the Treatment of Serious COVID-19: A Promising Therapy?. Pharm Med 34, 223–231 (2020).
-
Authors:Atal, S., Fatima, Z.
3. Computer-aided prediction and design of IL-6 inducing peptides: IL-6 plays a crucial role in COVID-19. Briefings in Bioinformatics. 2021, 22(2): 936–945.
-
Authors:Anjali Dhall et al.
4. Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis. JAMA. 2021, 326(6):499–518.
-
Authors: The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group.
5. Why tocilizumab could be an effective treatment for severe COVID-19?. J Transl Med 18, 164 (2020).
-
Authors:Fu, B., Xu, X. & Wei, H.
- Background
- Product Features
- Product List
- Verification Data
- References